Ana L Costa1,2, Catarina Moreira-Barbosa1, João Lobo1,3,4, Bárbara Vilela-Salgueiro1, Mariana Cantante1,3, Rita Guimarães1,3, Paula Lopes1,3, Isaac Braga5, Jorge Oliveira5, Luís Antunes6, Rui Henrique1,3,4, Carmen Jerónimo1,4. 1. Cancer Biology & Epigenetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal. 2. Master in Oncology, Institute of Biomedical Sciences Abel Salazar - University of Porto (ICBAS-UP), Porto, Portugal. 3. Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal. 4. Department of Pathology & Molecular Immunology, Institute of Biomedical Sciences Abel Salazar - University of Porto (ICBAS-UP), Porto, Portugal. 5. Department of Urology, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal. 6. Department of Epidemiology, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
Abstract
AIM: Assess differential patterns of selected five genes' promoter methylation among testicular germ cell tumors (TGCT) subtypes. MATERIALS & METHODS: CRIPTO, HOXA9, MGMT, RASSF1A and SCGB3A1 promoter methylation levels were evaluated by quantitative methylation-specific PCR in 161 TGCT and 16 controls. Associations between clinicopathological parameters and promoter methylation levels were assessed, and receiver operating characteristics curve analysis was performed. RESULTS: Promoter methylation of CRIPTO/HOXA9/SCGB3A1 panel and RASSF1A best discriminated between controls and nonseminomatous tumors or seminomas, respectively, whereas HOXA9/RASSF1A panel displayed the best discriminative performance between nonseminomatous tumor and seminomas. Significant differences in CRIPTO, MGMT and RASSF1A methylation levels were depicted between pure forms and matched mixed components of seminomas and embryonal carcinoma. HOXA9, RASSF1A and SCGB3A1 promoter methylation significantly associated with tumor stage. CONCLUSION: Different combinations of five genes' promoter methylation levels discriminate among TGCT subtypes. Methylation patterns may also assist in identification of more clinically aggressive tumors.
AIM: Assess differential patterns of selected five genes' promoter methylation among testicular germ cell tumors (TGCT) subtypes. MATERIALS & METHODS:CRIPTO, HOXA9, MGMT, RASSF1A and SCGB3A1 promoter methylation levels were evaluated by quantitative methylation-specific PCR in 161 TGCT and 16 controls. Associations between clinicopathological parameters and promoter methylation levels were assessed, and receiver operating characteristics curve analysis was performed. RESULTS: Promoter methylation of CRIPTO/HOXA9/SCGB3A1 panel and RASSF1A best discriminated between controls and nonseminomatous tumors or seminomas, respectively, whereas HOXA9/RASSF1A panel displayed the best discriminative performance between nonseminomatous tumor and seminomas. Significant differences in CRIPTO, MGMT and RASSF1A methylation levels were depicted between pure forms and matched mixed components of seminomas and embryonal carcinoma. HOXA9, RASSF1A and SCGB3A1 promoter methylation significantly associated with tumor stage. CONCLUSION: Different combinations of five genes' promoter methylation levels discriminate among TGCT subtypes. Methylation patterns may also assist in identification of more clinically aggressive tumors.
Entities:
Keywords:
DNA methylation biomarkers; prognosis; testicular germ cell tumors
Authors: João Lobo; Ana Laura Costa; Mariana Cantante; Rita Guimarães; Paula Lopes; Luís Antunes; Isaac Braga; Jorge Oliveira; Mattia Pelizzola; Rui Henrique; Carmen Jerónimo Journal: J Transl Med Date: 2019-03-12 Impact factor: 5.531
Authors: João Lobo; Sandra P Nunes; Ad J M Gillis; Daniela Barros-Silva; Vera Miranda-Gonçalves; Annette van den Berg; Mariana Cantante; Rita Guimarães; Rui Henrique; Carmen Jerónimo; Leendert H J Looijenga Journal: Cancers (Basel) Date: 2019-09-17 Impact factor: 6.639
Authors: Elisa Rodrigues Sousa; Eugenio Zoni; Sofia Karkampouna; Federico La Manna; Peter C Gray; Marta De Menna; Marianna Kruithof-de Julio Journal: Cancers (Basel) Date: 2020-06-05 Impact factor: 6.639
Authors: Cassy M Spiller; João Lobo; Willem P A Boellaard; Ad J M Gillis; Josephine Bowles; Leendert H J Looijenga Journal: Cancers (Basel) Date: 2020-03-23 Impact factor: 6.639
Authors: Cecilie Bucher-Johannessen; Christian M Page; Trine B Haugen; Marcin W Wojewodzic; Sophie D Fosså; Tom Grotmol; Hege S Haugnes; Trine B Rounge Journal: Clin Epigenetics Date: 2019-12-03 Impact factor: 6.551